← 返回

CAR-T 细胞疗法在难治性多发性骨髓瘤患者中显示令人瞩目的结局:三分之一患者无需维持或后续治疗,5 年及以上无疾病进展

英文原题:CAR T-cell therapy shows impressive outcomes for patients with refractory multiple myeloma: One third of patients did not need maintenance or subsequent treatment and presented without disease progression at 5 years and beyond.

查看英文原题

CAR T-cell therapy shows impressive outcomes for patients with refractory multiple myeloma: One third of patients did not need maintenance or subsequent treatment and presented without disease progression at 5 years and beyond.

PubMed 2025/10/15(内容时间) Cancer Q1 · IF 5.6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

摘要

这条来源本身就没有摘要(PubMed 未提供),不是「还没翻译」。可以点最下面的「在 PubMed 查看」打开原文献页面。

论文信息

作者
Nierengarten MB
文献类型
新闻
期刊
Cancer2025 Oct 15
原文标识
PubMed 41104638 · DOI 10.1002/cncr.70057